Y. Suminami et al., IN-SITU INTERLEUKIN-4 GENE-EXPRESSION IN CANCER-PATIENTS TREATED WITHGENETICALLY-MODIFIED TUMOR VACCINE, Journal of immunotherapy with emphasis on tumor immunology, 17(4), 1995, pp. 238-248
Citations number
31
Categorie Soggetti
Immunology,Oncology,"Medicine, Research & Experimental
Patients with advanced malignancies, participating in our ongoing phas
e I interleukin-4 (IL-4) gene therapy protocol at the Pittsburgh Cance
r Institute, were vaccinated with irradiated autologous tumor cells to
gether with IL-4 gene-transduced irradiated autologous fibroblasts. Th
e level of expression of the IL-4 gene in cultured transduced and sele
cted fibroblasts and in biopsies obtained from vaccination sites was e
valuated using quantitative reverse transcription-polymerase chain rea
ction (RT-PCR), The number of copies of IL-4 mRNA/ng of total cellular
RNA was determined in the transduced fibroblasts. Good agreement was
observed between IL-4 message expression, as determined by RT-PCR, and
IL-4 production, as determined by enzyme-linked immunosorbent assay (
ELISA) in the fibroblast supernatants. Tissue biopsies of multiple vac
cination sites were obtained from the patients to determine the level
of gene expression in situ for IL-4 and Neo-r. The Neo-r gene was used
as a marker for transduced fibroblasts. Two weeks after the first vac
cination, mRNA for the IL-4 gene was still detectable in all tissue bi
opsies. The Neo-r gene was also detectable, indicating the presence of
transduced fibroblasts in the biopsy. After the second vaccination, e
xpression of the IL-4 and Neo-r genes was generally the highest on day
1 after vaccine administration and was considerably lower but still d
etectable on day 14 in all biopsies tested. These data indicate that a
utologous dermal fibroblasts transduced with the IL-4 and Neo-r genes
and used as a source of IL-4 in tumor vaccine are able to express the
IL-4 gene in vivo.